Trials / Unknown
UnknownNCT00792779
Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Centro Medico Campinas · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if propofol could protect erythrocytes by directly scavenging free radicals from the blood current and increasing resistance of their cell membranes in patients submitted to gastroplasty.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propofol | Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus. |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-05-01
- Completion
- 2009-06-01
- First posted
- 2008-11-18
- Last updated
- 2009-11-05
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00792779. Inclusion in this directory is not an endorsement.